IP Library › Granted Patent US 12,419,944
Granted Patent B2
US 12,419,944 · App. 18/047,619 · Granted Sep 23, 2025

DNABII vaccines and antibodies with enhanced activity

Inventors: Lauren O. Bakaletz (Hilliard, OH); Steven D. Goodman (Hilliard, OH)
Assignee: Research Institute at Nationwide Children's Hospital
A61K39/102A01N63/50A61K45/06A61P31/04C07K14/285C07K16/1242G01N33/56911A61K38/00A61K2039/505C07K2317/20C07K2317/24C07K2317/55C07K2319/00G01N2333/285
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,944
App. No.
18/047,619
Granted
Sep 23, 2025
Kind
B2
Abstract

The disclosure provides methods and compositions that are useful to lessen and/or cure bacterial biofilms and treat diseases or disorders associated with biofilms using one or more novel polypeptide vaccines, antibodies, antibody fragments and compositions. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the host's immune system and/or traditional antibiotics.

Claims (54)

1. A polynucleotide encoding a polypeptide comprising the polypeptide of SEQ ID NO: 50.

2. A composition comprising the polynucleotide of claim 1 and a pharmaceutically acceptable carrier.

3. The composition of claim 2 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

4. A vaccine composition comprising an effective amount of the polynucleotide of claim 1 and a pharmaceutically acceptable carrier.

5. The vaccine composition of claim 4 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

6. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a polynucleotide of claim 1 .

7. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 2 .

8. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 4 .

9. A polynucleotide encoding a polypeptide comprising the peptide of SEQ ID NO: 12 (FLEEIRLSLESGQDVKLSGF) and the peptide of SEQ ID NO: 15 (TLSAKEIENMVKDILEFISQ).

10. The polynucleotide of claim 9 , wherein the peptide of SEQ ID NO: 12 and the peptide of SEQ ID NO: 15 are joined via a linker polypeptide comprising the peptide of SEQ ID NO: 44 (GPSL).

11. A composition comprising the polynucleotide of claim 9 and a pharmaceutically acceptable carrier.

12. A composition comprising the polynucleotide of claim 10 and a pharmaceutically acceptable carrier.

13. A polynucleotide encoding a polypeptide comprising the peptide of SEQ ID NO: 13 (RPGRNPKTGDVVPVSARRVV) and the peptide of SEQ ID NO: 17 (FSLHHRQPRLGRNPKTGDSV).

14. The polynucleotide of claim 13 , wherein the peptide of SEQ ID NO: 13 and the peptide of SEQ ID NO: 17 are joined via a linker polypeptide comprising the peptide of SEQ ID NO: 44 (GPSL).

15. A composition comprising the polynucleotide of claim 13 and a pharmaceutically acceptable carrier.

16. A composition comprising the polynucleotide of claim 14 and a pharmaceutically acceptable carrier.

17. A vaccine composition comprising an effective amount of the polynucleotide of claim 13 and a pharmaceutically acceptable carrier.

18. A vaccine composition comprising an effective amount of the polynucleotide of claim 14 and a pharmaceutically acceptable carrier.

19. The composition of claim 15 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

20. The composition of claim 16 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

21. The vaccine composition of claim 17 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

22. The vaccine composition of claim 18 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

23. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a polynucleotide of claim 13 .

24. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of a polynucleotide of claim 14 .

25. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 15 .

26. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 16 .

27. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 17 .

28. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 18 .

29. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 19 .

30. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 20 .

31. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 21 .

32. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 22 .

33. A polynucleotide encoding a polypeptide consisting of the polypeptide of SEQ ID NO: 50.

34. A composition comprising the polynucleotide of claim 33 and a pharmaceutically acceptable carrier.

35. The composition of claim 34 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

36. A vaccine composition comprising an effective amount of the polynucleotide of claim 33 and a pharmaceutically acceptable carrier.

37. The vaccine composition of claim 36 , further comprising one or more of an adjuvant, a preservative, a stabilizer, an antibiotic or an additional active ingredient.

38. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the polynucleotide of claim 33 .

39. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 34 .

40. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the composition of claim 35 .

41. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 36 .

42. A method to disrupt or prevent the formation of a biofilm in a subject in need thereof, comprising administering to the subject an effective amount of the vaccine composition of claim 37 .

43. The polynucleotide of claim 1 , comprising DNA.

44. The polynucleotide of claim 1 , comprising RNA.

45. The polynucleotide of claim 1 , wherein the polynucleotide is a messenger RNA (mRNA).

46. The polynucleotide of claim 1 , further comprising one or more regulatory elements.

47. A vector comprising the polynucleotide of claim 1 .

48. A host cell comprising the polynucleotide of claim 1 .

49. The polynucleotide of claim 33 , comprising DNA.

50. The polynucleotide of claim 33 , comprising RNA.

51. The polynucleotide of claim 33 , wherein the polynucleotide is a messenger RNA (mRNA).

52. The polynucleotide of claim 33 , further comprising one or more regulatory elements.

53. A vector comprising the polynucleotide of claim 33 .

54. A host cell comprising the polynucleotide of claim 33 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2022
From: BAKALETZ, LAUREN O.; GOODMAN, STEVEN D.
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 061461/0459 →
Continuity (5)
Division 16475656
Provisional Application 62455437 · Feb 6, 2017
Provisional Application 62453921 · Feb 2, 2017
Provisional Application 62442307 · Jan 4, 2017
Related Publication 20230190908A1 · Jun 22, 2023
References Cited (287)
US 6551795B1 · Rubenfield et al. · 2003 [cited by applicant]
US 6663863B2 · Horvath et al. · 2003 [cited by applicant]
US 6696550B2 · Larosa et al. · 2004 [cited by applicant]
US 6846651B2 · Fleischmann et al. · 2005 [cited by applicant]
US 7241867B2 · Bakaletz et al. · 2007 [cited by applicant]
US 7413868B2 · Kauvar et al. · 2008 [cited by applicant]
US 7638282B2 · Bakaletz et al. · 2009 [cited by applicant]
US 7811591B2 · Bakaletz et al. · 2010 [cited by applicant]
US 7816086B2 · Bakaletz et al. · 2010 [cited by applicant]
US 7939344B2 · Kauvar et al. · 2011 [cited by applicant]
US 7998490B2 · Bakaletz et al. · 2011 [cited by applicant]
US 8236494B2 · Bakaletz et al. · 2012 [cited by applicant]
US 8283114B2 · Bakaletz et al. · 2012 [cited by applicant]
US 8628917B2 · Bakaletz et al. · 2014 [cited by applicant]
US 8652773B2 · Bakaletz et al. · 2014 [cited by applicant]
US 8758764B2 · Masignani et al. · 2014 [cited by applicant]
US 8933029B2 · Mcnicol et al. · 2015 [cited by applicant]
US 8999291B2 · Goodman · 2015 [cited by examiner]
US 9017656B2 · Hancock et al. · 2015 [cited by applicant]
US 9034642B2 · Bakaletz et al. · 2015 [cited by applicant]
US 9155792B2 · Cottarel et al. · 2015 [cited by applicant]
US 9745366B2 · Goodman et al. · 2017 [cited by applicant]
US 10233234B2 · Kauvar et al. · 2019 [cited by applicant]
US 10570193B2 · Kauvar et al. · 2020 [cited by applicant]
US 10940204B2 · Bakaletz et al. · 2021 [cited by applicant]
US 11497780B2 · Goodman et al. · 2022 [cited by applicant]
US 20030099602A1 · Levin et al. · 2003 [cited by applicant]
US 20030229065A1 · Levy et al. · 2003 [cited by applicant]
US 20040202670A1 · Apicella · 2004 [cited by applicant]
US 20050049402A1 · Babcook et al. · 2005 [cited by applicant]
US 20050131222A1 · Fleischmann et al. · 2005 [cited by applicant]
US 20050221439A1 · Bakaletz et al. · 2005 [cited by applicant]
US 20060030539A1 · Nick et al. · 2006 [cited by applicant]
US 20060228384A1 · Eldridge · 2006 [cited by applicant]
US 20060240045A1 · Berthet et al. · 2006 [cited by applicant]
US 20070207210A1 · Brown et al. · 2007 [cited by applicant]
US 20070264256A1 · Bakaletz et al. · 2007 [cited by applicant]
US 20080267966A1 · Masignani et al. · 2008 [cited by applicant]
US 20090029929A1 · Nakajima et al. · 2009 [cited by applicant]
US 20090297555A1 · Kemble et al. · 2009 [cited by applicant]
US 20090324651A1 · Old et al. · 2009 [cited by applicant]
US 20100166771A1 · Bakaletz et al. · 2010 [cited by applicant]
US 20100291177A1 · Hermans et al. · 2010 [cited by applicant]
US 20100310569A1 · Bakaletz et al. · 2010 [cited by applicant]
US 20110135646A1 · Bakaletz et al. · 2011 [cited by applicant]
US 20110236306A1 · Goodman et al. · 2011 [cited by applicant]
US 20110293624A1 · Bakaletz et al. · 2011 [cited by applicant]
US 20120128701A1 · Goodman et al. · 2012 [cited by applicant]
US 20120148615A1 · Masignani et al. · 2012 [cited by applicant]
US 20130017204A1 · Bakaletz et al. · 2013 [cited by applicant]
US 20130078254A1 · Bakaletz et al. · 2013 [cited by applicant]
US 20130183323A1 · Wang · 2013 [cited by applicant]
US 20140120107A1 · Bakaletz et al. · 2014 [cited by applicant]
US 20140127221A1 · Bakaletz et al. · 2014 [cited by applicant]
US 20140287426A1 · Arnold et al. · 2014 [cited by applicant]
US 20140356389A1 · Masignani et al. · 2014 [cited by applicant]
US 20150086542A1 · Goodman et al. · 2015 [cited by applicant]
US 20150086561A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150166641A1 · Goodman et al. · 2015 [cited by applicant]
US 20150197558A1 · Kauvar et al. · 2015 [cited by applicant]
US 20150216971A1 · Rotolo et al. · 2015 [cited by applicant]
US 20150218231A1 · Bakaletz et al. · 2015 [cited by applicant]
US 20150299298A1 · Kauvar et al. · 2015 [cited by applicant]
US 20160175440A1 · Goodman et al. · 2016 [cited by applicant]
US 20160194384A1 · Goodman et al. · 2016 [cited by applicant]
US 20160237145A1 · Kauvar et al. · 2016 [cited by applicant]
US 20160244489A1 · Masignani et al. · 2016 [cited by applicant]
US 20160289278A1 · Bakaletz et al. · 2016 [cited by applicant]
US 20160340650A1 · Wagner et al. · 2016 [cited by applicant]
US 20170182205A1 · Zupancic et al. · 2017 [cited by applicant]
US 20180303900A1 · Bakaletz et al. · 2018 [cited by applicant]
US 20190000971A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20190040127A1 · Wadehra et al. · 2019 [cited by applicant]
US 20190338018A1 · Bakaletz et al. · 2019 [cited by applicant]
US 20200002409A1 · Goodman et al. · 2020 [cited by applicant]
US 20200190170A1 · Kauvar et al. · 2020 [cited by applicant]
US 20210206841A1 · Goodman et al. · 2021 [cited by applicant]
JP 2016521752A · 2016 [cited by applicant]
JP 2016538824A · 2016 [cited by applicant]
WO WO02085295 · 2002 [cited by applicant]
WO WO2004014418A2 · 2004 [cited by applicant]
WO WO2004078949A2 · 2004 [cited by applicant]
WO WO2005111066A2 · 2005 [cited by applicant]
WO WO2006017816A2 · 2006 [cited by applicant]
WO WO2006138527 · 2006 [cited by applicant]
WO WO2009006699A1 · 2009 [cited by applicant]
WO WO2011123396A1 · 2011 [cited by applicant]
WO WO2014201305A1 · 2014 [cited by applicant]
WO WO2015038339A1 · 2015 [cited by applicant]
WO WO2015048484A2 · 2015 [cited by applicant]
WO WO2016154491A1 · 2016 [cited by applicant]
WO WO2017023863A1 · 2017 [cited by applicant]
WO WO2017066719A2 · 2017 [cited by applicant]
WO WO2017192594A1 · 2017 [cited by applicant]
WO WO2018042385A2 · 2018 [cited by applicant]
WO WO2018129092A1 · 2018 [cited by applicant]
WO WO2018170178A1 · 2018 [cited by applicant]
WO WO2021007260A2 · 2021 [cited by applicant]
Devaraj et al., “The DNABII family of proteins is comprised of the only nucleoid associated proteins required for nontypeable Haemophilus influenzae biofilm structure”, MicrobiologyOpen, 2018, 13 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 15/999,215, dated Aug. 6, 2021, 8 pages. [cited by applicant]
Notice of Allowance in U.S. Appl. No. 17/552,986, dated Nov. 16, 2022, 8 pages. [cited by applicant]
Novotny, et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo”, EBioMedicine 10 (2016), pp. 33-44. [cited by applicant]
Trifiro et al., “Ghost Mycobacteria on Gram Stain,” Journal of Clinical Microbiology, Jan. 1990, vol. 28, No. 1, pp. 146-147. [cited by applicant]
U.S. Notice of Allowance dated Jun. 24, 2024, for U.S. Appl. No. 16/475,654. [cited by applicant]
U.S. Appl. No. 15/999,215, filed Aug. 16, 2018, Goodman et al. [cited by applicant]
U.S. Appl. No. 16/297,094, filed Mar. 8, 2019, Goodman et al. [cited by applicant]
U.S. Appl. No. 16/475,654, filed Jul. 2, 2019, Bakaletz et al. [cited by applicant]
U.S. Appl. No. 16/475,656, filed Jul. 2, 2019, Bakaletz et al. [cited by applicant]
Adams et al., “D-158. Epitope-mapping the immune response of children with otitis media and adults with chronic obstructive pulmonary disease to the PilA protein of nontypeable Haemophilus influenzae type IV pilus,” 107… [cited by applicant]
Adams et al., “Epitope-mapping the immune response of children with otitis media and adults with chronic obstructive pulmonary disease to the PilA protein of nontypeable Haemophilus influenzae type IV pilus,” Immunology… [cited by applicant]
Bakaletz et al., “New strategies to target bacterial biofilms”, 28th Annual North American Cystic Fibrosis Conference (NACFC), Atlanta, GA, Oct. 9-11, 2014 (presentation), 2 pages. [cited by applicant]
Bakaletz et al., “Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chincilla,” Vaccine, v… [cited by applicant]
Bakaletz et al., “Protection against Development of Otitis Media Induced by Nontypeable Haemophilus influenzae by Both Active and Passive Immunization in a Chinchilla Model of Virus-Bacterium Superinfection,” Infecion a… [cited by applicant]
Bakaletz, “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid associated proteins”, 6th ASM Conference on Biofilms, Miami, FL, Sep. 29-Oct. 4, 2012 (presentation), 5 pages. [cited by applicant]
Bakaletz, L.O., Targeting the biofilm for development of novel preventative and therapeutic vaccine candidates to prevent otitis media, 6th ASM Conference on Biofilms, Miami, FL, Sep. 29-Oct. 4, 2012 (presentation), 5 p… [cited by applicant]
Bass, J.I.F. et al. (2010) “Extracellular Dna: A Major Proinflammatory Component of Pseudomonas aeruginosa Biofilms,” The Journal of Immunology 184:6386-6395. [cited by applicant]
Beech, I.B. et al. (2005) “Microbe-surface interactions in biofouling and biocorrosion processes,” International Microbiology 8:157-168. [cited by applicant]
Bjarnsholt, T. (2013) “The role of bacterial biofilms in chronic infections,” APMIS 121(Suppl. 136):1-51. [cited by applicant]
Boles, B.R. et al. (2011) “Staphylococcal biofilm disassembly,” Trends in Microbiology 19(9):449-455. [cited by applicant]
Brady, R.A. et al. (2006) “Identification of [cited by applicant]
Brandstetter et al., “Antibodies Directed Against Integration Host Factor Mediate Biofilm Clearance From Nasopore,” The Laryngoscope, vol. 12, No. 11, Nov. 2013, pp. 2626-2632. [cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor-mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258, Supp… [cited by applicant]
Brockson et al., “Evaluation of the kinetics and mechanism of action of anti-integration host factor- mediated disruption of bacterial biofilms,” Molecular Microbiology, vol. 93, No. 6, Aug. 19, 2014, pp. 1246-1258. [cited by applicant]
Brockson ME, Novotny LA, Mokrzan EM, Malhotra S, Jurcisek JA, Akbar R, Devaraj A, Goodman SD, Bakaletz LO, Evaluation of the kinetics and mechanism of action of anti -integration host factor- mediated disruption of bact… [cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VHCDR2”, J. Immunol. May 1996, 155(9):3285-3291. [cited by applicant]
Catlin, “Extracellular Deoxyribonucleic Acid of Bacteria and a Deoxyribonuclease Inhibitor,” Science, vol. 124, Sep. 7, 1956, pp. 441-442. [cited by applicant]
Chen et al., “Novel Strategies for the Prevention and Treatment of Biofilm Related Infections,” Int. J. Mol. Sci., vol. 14, Sep. 6, 2013, pp. 18488-18501. [cited by applicant]
Chen, C. et al. (2004) “Substrate specificity of Helicobacter pylori histone-like HU protein is determined by insufficient stabilization of DNA flexure points,” Biochem J. 383:343-351. [cited by applicant]
Coenye, T. et al. (2010) “In vitro and in vivo model systems to study microbial biofilm formation,” Journal of Microbiological Methods 83:89-105. [cited by applicant]
Cohavy, O. et al. (1999) “Identification of a Novel Mycobacterial Histone H1 Homologue (HupB) as an Antigenic Target of pANCA Monoclonal Antibody and Serum Immunoglobulin A from Patients with Cohn's Disease,” Infection … [cited by applicant]
Collarini, E.J. et al. (2009) “Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients,” J Immunol 183:6338-6345. [cited by applicant]
Dalai, B. et al. (2009) “Histone-like protein H-NS regulates biofilm formation and virulence of Actinobacillus pheuropneumonia,” Microbial Pathogenesis 46:128-134. [cited by applicant]
Darouiche, R.O. et al. (2004) “Treatment of Infections Associated with Surgical Implants, ” N Engl J Med 350:1422-1429. [cited by applicant]
De La Fuente-Nunez et al., “Broad-Spectrum Anti-biofilm Peptide That Targets a Cellular Stress Response,” PLOS Pathog., vol. 10, No. 5, May 2014, pp. 1-12. [cited by applicant]
Devaraj et al., “DNABII proteins play a central role in UPEC biofilm structure”, Molecular Microbiology, 2015, vol. 96, vol. 6, Jun. 2015, pp. 1119-1135. [cited by applicant]
Dominguez-Herrera, J et al. (2011) “Efficacy of Daptomycin versus Vancomycin in an Experimental Model of Foreign-Body and Systemic Infection Caused by Biofilm Producers and Methicillin-Resistant Staphylococcus epidermid… [cited by applicant]
Donlan, R.M. et al. (2002) “Biofilms: Survival Mechanisms of Clinically Relevant Microorganisms,” Clinical Microbiology Reviews 15(2):167-193. [cited by applicant]
Durocher et al., “High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells,” Nucleic Acids Research, vol. 30, No. 2, e9, Nov. 11, 2001, 9 pages. [cited by applicant]
Eboigbodin, K.E. et al. (2008) “Characterization of the Extracellular Plymeric Substances Produced by Escherichia coli Using Infrared Spectroscopic, Proteomic, and Aggregation Studies,” Biomacromolecules 9:686-695. [cited by applicant]
Estelles et al., “A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model,” Antimicrobial Agents and Chemotherapy… [cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections”, Pharamceuticals, vol. 3, No. 5, May 11, 2010, pp. 1374-1393. [cited by applicant]
Estrela et al., “Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections,” Pharmaceuticals, vol. 3, May 11, 2010, pp. 1374-1393. [cited by applicant]
Garcia-Contreras et al., “Protein Translation and Cell Death: The Role of Rare tRNAs in Biofilm Formation and in Activating Dormant Phage Killer Genes,” PLoS One, vol. 3, No. 6, Jun. 11, 2008, e2394, 17 pages. [cited by applicant]
George et al., “Cystic fibrosis infections: treatment strategies and prospects,” FEMS Microbiol Lett., vol. 300, Jun. 15, 2009, pp. 153-164. [cited by applicant]
Gerstel et al., “Complex Regulation of csgD Promoter Activity by Global Regulatory Proteins,” Molecular Microbiology, vol. 49, No. 3, Aug. 2003, pp. 639-654. [cited by applicant]
Goldenberg et al., “Genetic and biochemical analysis of IHF/HU hybrid proteins”, BioChimie, vol. 76, No. 10-11, Jan. 1, 1994, pp. 941-950. [cited by applicant]
Goodman et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins,” Mucosal Immunology, vol. 4, No. 6, Nov. 2011, pp. 625-637. [cited by applicant]
Goodman et al., “In Vitro Selection of Integration Host Factor Binding Sites,” Journal of Bacteriology, vol. 181, No. 10, May 1999, pp. 3246-3255. [cited by applicant]
Goodman et al., “Replacement of Integration Host Factor Protein-induced DNA Bending by Flexible Regions of DNA,” The Journal of Biological Chemistry, vol. 274, No. 52, Aug. 6, 1999, pp. 37004-37011. [cited by applicant]
Goodman S D et al., “Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins”, Mucosal Immuno, Nature Publishing Group, vol. 4, No. 6, Nov. 1, 2011, pp. 625-6… [cited by applicant]
Goodman, “A new immunotherapeutic approach that disperses biofilms, Banff Conference on Infectious Diseases”, Banff, Alberta, Canada, May 18, 2012 (presentation), 9 pages. [cited by applicant]
Goodman, “Making and breaking biofilms”, Ohio Branch American Society for Microbiology Annual Meeting, Columbus, OH, Apr. 11-12, 2014 (presentation), 12 pages. [cited by applicant]
Goodman, “Nucleoprotein complexes in the extracellular matrix are critical for the structural integrity of bacterial biofilms”, 112th General Meeting, American Society for Microbiology, San Francisco, CA, Jun. 18, 2012 … [cited by applicant]
Goodman, “The DNABII family of proteins: Diagnostic markers and therapeutic targets of bacterial biofilms”, International Congress on Bacteriology and Infectious Disease, Baltimore, MD, Nov. 21, 2013, 7 pages. [cited by applicant]
Goshima et al., “Chimeric HU-IHF proteins that alter DNA-binding ability,” GENE, vol. 118, No. 1, Sep. 1, 1992, pp. 97-102. [cited by applicant]
Govan et al., “Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia,” Microbiol. Rev., vol. 60, No. 3, Sep. 1996, pp. 539-574. [cited by applicant]
Granston et al., “Characterization of a Set of Integration Host Factor Mutants Deficient for DNA Binding,” J. Mol. Biol., vol. 234, Jun. 21, 1993, pp. 45-59. [cited by applicant]
Greenspan et al., “Defining epitopes: It's not as easy as it seems,” Nature Biotechnology, vol. 17, Oct. 1999, pp. 936-937. [cited by applicant]
Gustave et al., “Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 12, No. 4, Nov. 17, 2012, pp. 384-389. [cited by applicant]
Gustave et al., Biofilms recovered from the sputum of CF patients contain the bacterial protein integration host factor (IHF), 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA, Nov. 3-5, 2011 (poster),… [cited by applicant]
Gustave JE, Jurcisek JA, McCoy KS, Goodman SD, Bakaletz LO. Targeting bacterial integration host factor to disrupt biofilms associated with cystic fibrosis. Journal of cystic fibrosis : official journal of the European … [cited by applicant]
Hall-Stoodley et al., “Bacterial Biofilms: From the Natural Environment to Infectious Diseases,” Nature Reviews, Microbiology, vol. 2, Feb. 2004, pp. 95-108. [cited by applicant]
Hall-Stoodley et al., “Direct Detection of Bacterial Biofilms on the Middle-Ear Mucosa of Children With Chronic Otitis Media,” JAMA, vol. 296, No. 2, Jun. 1, 2007, pp. 202-211. [cited by applicant]
Hall-Stoodley et al., “Evolving concepts in biofilm infections”, Cellular Microbiology, vol. 11, No. 7, 2009, pp. 1034-1043. [cited by applicant]
Hall-Stoodley et al., “Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in [cited by applicant]
Haluzi et al., “Genes Coding for Integration Host Factor Are Conserve in Gram-Negative Bacteria,” Journal of Bacteriology, vol. 173, No. 19, Oct. 1991, pp. 6297-6299. [cited by applicant]
Harriman, W.D. et al. (2008) “Antibody discovery via multiplexed single cell characterization,” Journal of Immunological Methods 341:135-145. [cited by applicant]
Harrison, J.J. et al. (2010) “Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening,” Nature Protocols 5(7):1236-1254. [cited by applicant]
Haruta et al., “A possible role of histone-like DNA-binding protein of Streptococcus intermedius in the pathogenesis of bile duct damage in primary biliary cirrhosis,” Clinical Immunology, vol. 127, No. 2, Mar. 11, 2008… [cited by applicant]
Haruta et al., “Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation,” Laboratory Investigation, vol. 90, Apr. 2010, pp. 577-588. [cited by applicant]
Haurum. “Recombinant polyclonal antibodies: the next generation of antibody therapeutics?” Drug Discovery Today. Jul. 2006; 11(13-14):655-60. [cited by applicant]
Hoyle et al., “Bacterial Resistance to Antibiotics: The Role of Biofilms,” Prog. Drug Res., vol. 37, 1991, pp. 91-105. [cited by applicant]
Idicula, W.K. et al. (2016) “Identification of Biofilms in Post-tympanostomy Tube Otorrhea,” The Laryngoscope 126(8):1946-1951. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2018/012235 dated Mar. 18, 2019, 31 pages. [cited by applicant]
International Preliminary Report on Patentability on PCT PCT/US2018/012255 dated Jul. 18, 2019, 9 pages. [cited by applicant]
International Search Report and Written Opinion on PCT Application No. PCT/US2018/012235 dated Apr. 26, 2018, 19 pages. [cited by applicant]
Janeway, “Manipulating the immune response to fight infection,” Immunobiology: The Immune System in Health and Disease, 5th ed.; retrieved online from https://www.ncbi.nlm.nih.gov/books/NBK27131/, 2001, 13 pages. [cited by applicant]
Janeway, et al., “Immunobiology—The Immune System in Health and Disease,” Third Edition, 1997, Garland Publish Inc., 14 pages. [cited by applicant]
Jiao et al., “Identification of Biofilm Matrix-Associated Proteins from an Acid Mine Drainage Microbial Community,” Appl & Environ Microbiol., vol. 77, Aug. 2011, pp. 5230-5237. [cited by applicant]
Jodar et al., “Development of vaccines against meningococcal disease,” Lancet, vol. 359, Apr. 27, 2002, pp. 1499-1508. [cited by applicant]
John, A-K. et al. (2011) “Reversible Daptomycin Tolerance of Adherent Staphylococci in an Implant Infection Model,” Antimicrobial Agents and Chemotherapy 55(7):3510-3516. [cited by applicant]
Johnson et al., “Chapter 8: Bending and Compaction of DNA by Proteins,” Protein-Nucleic Acid Interactions: Structural Biology, 2008, pp. 176-220. [cited by applicant]
Joo, H-S. et al. (2012) “Molecular Basis of In Vivo Formation by Bacterial Pathogens,” Chemistry & Biology 19:1503-1513. [cited by applicant]
Jurcisek et al., “Role of Sialic Acid and Complex Carbohydrate Biosynthesis in Biofilm Formation by Nontypeable Haemophilus influenzae in the Chinchilla Middle Ear,” Infection and Immunity, vol. 73, Jun. 2005, pp. 3210-… [cited by applicant]
Jurcisek et al., “Biofilms Formed by Nontypeable Haemophilus influenzae In Vivo Contain both Double-Stranded DNA and Type IV Pilin Protein,” Journal of Bacteriology, vol. 189, No. 10, Feb. 15, 2007, pp. 3868-3875. [cited by applicant]
Jurcisek JA, Bakaletz LO. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. Journal of bacteriology.2007; 189(10):3868-75. Epub Feb. 27, 2007. doi:… [cited by applicant]
Justice et al., “Aberrant Community Architecture and Attenuated Persistence of Uropathogenic Escherichia coli in the Absence of Individual IHF Subunits,” PLoS ONE, vol. 7, No. 10, Oct. 2012, pp. 1-11. [cited by applicant]
Kamashev D, Rouviere-Yaniv J. The histone-like protein HU binds specifically to DNA recombination and repair intermediates. The EMBO journal.2000;19(23):6527-35. [cited by applicant]
Kamashev et al., “The histone-like protein HU binds specifically to DNA recombination and repair intermediates,” The EMBO Journal, vol. 19, No. 23, Oct. 13, 2000, pp. 6527-6535. [cited by applicant]
Kennedy et al., “Passive Transfer of Antiserum Specific for Immunogens Derived from a Nontypeable Haemophilus influenzae Adhesin and Lipoprotein D Prevents Otitis Media after Heterologous Challenge,” Infection and Immun… [cited by applicant]
Khrapunov, S. et al. (2006) “Binding then bending: A mechanism for wrapping Dna,” PNAS 103(51):19217-19218. [cited by applicant]
Kim et al., “Beta-Arm flexibility of HU from [cited by applicant]
Kim et al., “Proteins Released by Helicobacter pylori In Vitro,” Journal of Bacteriology, vol. 184, No. 22, Nov. 2002, pp. 6155-6162. [cited by applicant]
Kirketerp-Moller et al., “Distribution, Organization, and Ecology of Bacteria in Chronic Wounds,” Journal of Clinical Microbiology, vol. 46, No. 8, Aug. 2008, pp. 2717-2722. [cited by applicant]
Kristian, S.A. et al. (2003) “Alanylation of Teichoic Acids Protects [cited by applicant]
Kyd et al., “Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens tTo Induce Clearance of Nontypeable Haemophilus influenzae from the Rat Middle Ear and Lungs as Well as from the Ch… [cited by applicant]
Lappann M, Claus H, van Alen T, Harmsen M, Elias J, Molin S, Vogel U. A dual role of extracellular DNA during biofilm formation of Neisseria meningitidis. Molecular microbiology.2010;75(6):1355-71. doi: 10.1111/j.1365-2… [cited by applicant]
Laura A. Novotny et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo”, EBIOMEDICINE, vol. 10, Aug. 1, 2016, pp. 33-44. [cited by applicant]
Lebeaux et al., “From in vitro to in vivo Models of Bacterial Biofilm-Related Infections,” Pathogens, vol. 2, May 13, 2013, pp. 288-356. [cited by applicant]
Liu et al., “The essentiality and involvement of [cited by applicant]
Liu, D. et al. (2008) “Histone-like DNA binding protein of [cited by applicant]
Lunsford et al., “DNA-Binding Activities in Streptococcus gordonii: Indentification of a Receptor-Nickase and a Histonelike Protein,” Current Microbiology, vol. 32, 1996, pp. 95-100. [cited by applicant]
M. Elizabeth Brockson et al., “Evaluation of the kinetics and mechanism of action anti-integration host factor-mediated disruption of bacterial biofilms: Anti-IHF-mediated biofilm collapse”, Molecular Microbiology., Aug… [cited by applicant]
Malhotra et al., “Defining the functional epitopes of Integration Host Factor (IHF) to develop a novel biofilm-focused immunotherapeutic against nontypeable Haemophilus influenzae-induced chronic and recurrent otitis me… [cited by applicant]
Malhotra et al., “Fine mapping the functional epitopes within integration host factor, a novel therapeutic target for nontypeable Haemophilus influenza-induced diseases of the respiratory tract”, Abst. 12th Annual AMA R… [cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, 20th Annual Midwest Microbial Pathogenesis Meeting. The Ohio State University, Columbus, OH,… [cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, Abst. Seventh Extraordinary International Symposium on Recent Advances in Otitis Media, Stoc… [cited by applicant]
Malhotra et al., Identification of immunoprotective domains within the bacterial DNA-binding protein, integration host factor, Seventh Extraordinary International Symposium on Recent Advances in Otitis Media, Stockholm,… [cited by applicant]
Mann, E.E. et al. (2009) “Modulation of eDNA Release and Degradation Affects Staphylococcus aureus Biofilm Maturation,” PLoS ONE 4(6):e5822, 1-12. [cited by applicant]
Martinez-Antonio A et al. (2008), “Functional organization of [cited by applicant]
Mouw et al., “Shaping the Borrelia burgdorferi genome: crystal structure and binding properties of the DNA-bending protein Hbb,” Molecular Microbiology, vol. 63, No. 5, Jan. 22, 2007, pp. 1319-1330. [cited by applicant]
Mukherjee et al., “Quantitative protein expression and cell surface characteristics of [cited by applicant]
Murphy et al., “Microbial Interactions in the Respiratory Tract,” The Pediatric Infectious Disease Journal, vol. 28, No. 10, Oct. 2009, pp. S121-S126. [cited by applicant]
Murphy, T.F. et al. (2002) “Biofilm formation by nontypeable Haemophilus influenzae: strain variablitiy, outer membrane antigen expression and role of pili,” BMC Microbiology 2:7, 1-8. [cited by applicant]
Nash et al., “Overproduction of [cited by applicant]
NCBI Genebank: P0A6Y1 (Sep. 13, 2005), 7 pages. [cited by applicant]
Non-Final Office Action dated Aug. 2, 2021, from U.S. Appl. No. 16/475,656. [cited by applicant]
Non-Final Office Action dated Dec. 10, 2021, from U.S. Appl. No. 16/475,656. [cited by applicant]
Novotny et al. “Antibodies against the majority subunit of type IV Pili disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media” Mol… [cited by applicant]
Novotny et al., “Antibodies against the majority subunit of Type 1V pili disperse nontypeable Haemophilus influenza biofilms in a LuxS-dependent manner and confer therapeutics resolution of experimental otitis media,” M… [cited by applicant]
Novotny et al., “Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates,” Vaccine, vol. 28, No. 1, pp. 2… [cited by applicant]
Novotny et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo,” EBIOMEDICINE, vol. 10, pp. 33-44 (Aug. 1, 2016). [cited by applicant]
Novotny et al., “Structural Stability of Burkholderia cenocepacia Biofilms Is Reliant on eDNA Structure and Presence of a Bacterial Nucleic Acid Binding Protein,” PLOS ONE, vol. 8, No. 6, e67629, Jun. 2013, 15 pages. [cited by applicant]
Novotny et al., “Detection and characterization of pediatric serum antibody to the OMP P5-homologous adhesin of nontypeable Haemophilus influenzae during acute otitis media,” Vaccine, vol. 20, No. 29-30, Jun. 8, 2002, p… [cited by applicant]
Novotny et al., Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates, Vaccine, vol. 28, No. 1, Aug. 22… [cited by applicant]
Novotny et al., “Epitope mapping of the Outer Membrane Protein P5-Homologous Fimbrin Adhesin of Nontypeable Haemophilus influenzae,” Infection and Immunity, vol. 68, No. 4, Apr. 2000, pp. 2119-2128. [cited by applicant]
Novotny et al., “Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae,… [cited by applicant]
Novotny et al., “The Fourth Surface-Exposed Region of the Outer Membrane Protein P5-Homologous Adhesin of the Nontypable Haemophilus influenzae Is an Immunodominant But Nonprotective Decoying Epitope,” The Journal of Im… [cited by applicant]
Novotny LA, Amer AO, Brockson ME, Goodman SD, Bakaletz LO. Structural stability of Burkholderia cenocepacia biofilms is reliant on eDNA structure and presence of a bacterial nucleic acid binding protein. PloS one.2013;8… [cited by applicant]
Novotny, “Development of a novel biofilm-focused immunotherapeutic against NTHI-induced otitis media”, 18th International Symposium on Recent Advances in Otitis Media, National Harbor, MD, Jun. 7-11, 2015 (presentation)… [cited by applicant]
Novotny, et al., “Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo,” 2016, EBioMedicine 10:33-44. [cited by applicant]
Novotny, et al., “Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae”, Mucosal Immunol vol. 5 no. 1, Jul. 2011, pp… [cited by applicant]
Oberto et al., “Histones, HMG, HU, IHF: Même combat,” Biochimie, vol. 76, 1994, pp. 901-908. [cited by applicant]
Ordway et al., “Evaluation of Standard Chemotherapy in the Guinea Pig Model of Tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 54, May 2010, pp. 1820-1833. [cited by applicant]
Otto, “ [cited by applicant]
PDB ID: 1IHF: Rice, P.A. et al. (1996), 1 page; retrieved online from http://www.rcsb.org/pdb/explore.do?structureld=IHF, 2 pages. [cited by applicant]
Pedulla et al., “A novel host factor for integration of mycobacteriophage L5,” Proc. Natl. Acad. Sci. USA, vol. 93, Dec. 1996, pp. 15411-15416. [cited by applicant]
Percival, S.L. et al. (2015) “Biofilms and Wounds: An Overview of the Evidence,” Advances in Wound Care 4(7):373-381. [cited by applicant]
Petersen et al., “Biofilm Mode of Growth of [cited by applicant]
Pethe et al., “Mycobacterium smegmatis laminin-binding glycoprotein shares epitopes with Mycobacterium tuberculosis heparin-binding haemagglutinin,” Molecular Microbiology, vol. 39, No. 1, 2001, pp. 89-99. [cited by applicant]
Priyadarshini R, Cugini C, Amdt A, Chen T, Tjokro NO, Goodman SD, Davey ME, The nucleoid- associated protein HUß affects global gene expression in Porphyromonas gingivalis. Microbiology. 2013; 159(Pt 2):219-29.First Pub… [cited by applicant]
Prymula et al., “Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both [cited by applicant]
Reffuveille et al., “A Broad-Spectrum Antibiofilm Peptide Enhances Antibiotic Action against Bacterial Biofilms”, Antimicrobial Agents and Chemotherapy, vol. 58, No. 9, Sep. 2014, pp. 5363-5371. [cited by applicant]
Rice et al., “Crystal Structure of an IHF-DNA Complex: A Protein-Induced DNA U-Turn,” CELL, vol. 87, No. 7, pp. 1295-1306 (Dec. 27, 1996). [cited by applicant]
Rice et al., “Crystal Structure of an IHF-DNA Complex: A Protein-Induced DNA U-Turn,” Cell, vol. 87, No. 7, Dec. 27, 1996, pp. 1295-1306. [cited by applicant]
Rocco et al. “Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics” Mol Oral Microbiol. Apr. 2017;32(2):118-1… [cited by applicant]
Rocco et al., “Natural antigenic differences in the fucntionally equivalent extracellular DNABI I proteins of bacterial biofilms provide a means for targeted biofilm therapeutics,” Molecular Oral Microbiology, vol. 32, … [cited by applicant]
Rouviere-Yaniv J, Gros F. Characterization of a novel, low-molecular-weight DNA- binding protein from Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America. 1975;72(9):3428-32… [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, vol. 79, No. 6, Mar. 1982, pp. 1979-1983. [cited by applicant]
Sapi et al., “Characterization of Biofilm Formation by Borrelia burgdorferi In Vitro,” PLOS One, vol. 7, No. 10, Oct. 2012, pp. 1-11. [cited by applicant]
Schwartz, K. et al. (2012) “Functional Amyloids Composed of Phenol Soluble Modulins Stabilize Staphylococcus aureus Biofilms,” PLOS Pathogens 8:e1002744, 1-11. [cited by applicant]
Segall et al., “Architectural elements in nucleoprotein complexes: interchangeability of specific and non-specific DNA binding proteins,” The EMBO Journal, vol. 13, No. 19, 1994, pp. 4536-4548. [cited by applicant]
Shahrooei et al., “Inhibition of Staphylococcus epidermidis Biofilm Formation by Rabbit Polyclonal Antibodies against the SesC Protein,” Infection and Immunity, vol. 77, No. 9, Sep. 2009, pp. 3670-3678. [cited by applicant]
Shields, R.C. et al. (2013) “Efficacy of a Marine Bacterial Nuclease against Biofilm Forming Microorganisms Isolated from Chronic Rhinosinusitis,” PLoS ONE 8(2):e55339, 1-13. [cited by applicant]
Singh et al., “Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms,” Nature, vol. 407, No. 12, Oct. 12, 2000, pp. 762-764. [cited by applicant]
Skolnick, J. et al. (2000) “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotechnology 18:34-39. [cited by applicant]
Smith et al., “Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface Fluid,” Cell, vol. 85, Apr. 19, 1996, pp. 229-236. [cited by applicant]
Stinson, M.W. et al. (1998) “Streptococcal Histone-Like Protein: Primary Structure of hlpA and Protein Binding to Lipoteichoic Acid and Epithelial Cells,” Infection and Immunity 66(1):259-265. [cited by applicant]
Stoltz et al., “Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth,” www.Science TranslationMedicine.org, vol. 2, No. 29, Apr. 28, 2010, pp. 1-8. [cited by applicant]
Sun et al., “Inhibition of Biofilm Formation by Monoclonal Antibodies against [cited by applicant]
Swinger et al., “IHF and HU: flexible architects of bent DNA,” Current Opinion in Structural Biology, vol. 14, No. 1, 2004, pp. 28-35. [cited by applicant]
Takeda, “Polyhistidine Affinity Chromatography for Purification and Biochemical Analysis of Fungal Cell Wall-Degrading Enzymes,” Affinity Chromatography, Dr. Sameh Magdeldin (Ed.), ISBN: 978-953-51-0325-7, In Tech, 2012… [cited by applicant]
Teter et al., “DNA Bending and Twisting Properties of Integration Host Factor Determined by DNA Cyclization,” Plasmid, vol. 43, 2000, pp. 73-84. [cited by applicant]
Tetz et al., “Effect of DNase and Antibiotics on Biofilm Characteristics,” Antimicrobial Agents and Chemotherapy, vol. 53, No. 3, Mar. 2009, pp. 1204-1209. [cited by applicant]
Thurnheer et al., “Colonisation of gingival epithelia by subgingival biofilms in vitro: role of ‘red complex’ bacteria”, Arch Oral Biol., vol. 59, No. 9, Sep. 2014, pp. 1-24. [cited by applicant]
Thurnheer et al., “Colonisation of gingival epithelia by subgingival biofilms in vitro: role of ‘red complex’ bacteria,” Archives in Oral Biology, vol. 59, No. 9, Sep. 2014, pp. 1-24. [cited by applicant]
Tjokro NO, Rocco CJ, Priyadarshini R, Davey ME, Goodman SD. A biochemical analysis of the interaction of Porphyromonas gingivalis HU PG0121 protein with DNA. PloS one. 2014;9(3):e93266. Epub Apr. 1, 2014 . doi: 10.1371. [cited by applicant]
UniProtKB/TrEMBL A0A0E4BIL9. Putative DNA-binding protein HU (Sep. 16, 2015) [Retrieved from the Internet Jan. 12, 2017: <http://www.uniprot.org/uniprot/A0A0E4BIL9.txt?version=3>], 1 page. [cited by applicant]
UniProtKB/TrEMBL A0A0E4BIL9. Putative DNA-binding protein HU (Sep. 16, 2015) [Retrieved from the Internet Jan. 12, 2017: ],1 page. [cited by applicant]
UniProtKB: TrEMBL A0A0E4BIL9. Putative DNA-binding protein HU, 2015, retrieved from www.uniprot.org/uniprot/A0A0E4BIL9.txt?version=3, 1 page. [cited by applicant]
US Final Office Action dated May 2, 2022, from U.S. Appl. No. 16/475,656. [cited by applicant]
US Notice of Allowance dated Jul. 21, 2022, from U.S. Appl. No. 16/475,656, 8 pages. [cited by applicant]
US Notice of Allowance dated Oct. 18, 2022, from U.S. Appl. No. 16/475,656. [cited by applicant]
US Office Action dated Feb. 17, 2021, from U.S. Appl. No. 16/475,656. [cited by applicant]
Vajdos et al. “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, J Mol. Biol., Jul. 5, 2002, 320(2), pp. 415-428. [cited by applicant]
Van Schaik et al., “DNA Binding: a Novel Function of Pseudomonas aeruginosa Type IV Pili,” Journal of Bacteriology, vol. 187, No. 4, Feb. 2005, pp. 1455-1464. [cited by applicant]
Whitchurch et al., “Extracellular DNA Required for Bacterial Biofilm Formation,” Science, vol. 295, No. 5559, Feb. 22, 2002, p. 1487, 1 page. [cited by applicant]
Whitchurch et al., “Extracellular DNA Required for Bacterial Biofilm Formation,” Science, vol. 295, No. 5559, Feb. 22, 2002, Supplementary Material, 2 pages. [cited by applicant]
Wiedenheft et al., “RNA-guided genetic silencing systems in bacteria and archaea,” Nature, vol. 482, No. 7385, Feb. 16, 2012, pp. 331-338. [cited by applicant]
Winters et al., “Isolation and Characterization of a [cited by applicant]
Winther et al., “Location of Bacterial Biofilm in the Mucus Overlying the Adenoid by Light Microscopy,” Head & Neck Surgery, vol. 135, No. 12, Dec. 2009, pp. 1239-1245. [cited by applicant]
Woischnig et al., “High Affinity Native Human Monoclonal Antibody with Broad Cross-Species Biofilm Disrupting Activity” poster presented at ICAAC Meeting on Sep. 20, 2015, available at www.trellisbio.com/assets/docs/ICA… [cited by applicant]
Woischnig et al., “High Affinity Native Human Monoclonal Antibody with Broad Cross-Species Biofilm Disrupting Activity”, ICAAC, Sep. 20, 2015, 1 page. [cited by applicant]
Xiong et al., “A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both [cited by applicant]
Zimmerli et al., “Pathogenesis of Foreign Body Infection: Description and Characteristics of an Animal Model,” The Journal of Infectious Diseases, vol. 146, No. 4, Oct. 1982, pp. 487-497. [cited by applicant]
Zimmerli, W. et al. (1984) “Pathogenesis of Foreign Body Infection,” J. Clin. Invest. 73:1191-1200. [cited by applicant]
Zulianello et al., “The HimA and HimD subunits of integration host factor can specifically bind to DNA as homodimers,” The EMBO Journal, vol. 13, No. 4, Apr. 1, 1994, pp. 1534-1540. [cited by applicant]